Literature DB >> 24440584

Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice.

Mathieu Frindel1, Nathalie Camus2, Aurore Rauscher1, Mickaël Bourgeois3, Cyrille Alliot3, Louisa Barré4, Jean-François Gestin1, Raphaël Tripier5, Alain Faivre-Chauvet6.   

Abstract

INTRODUCTION: HTE1PA, a monopicolinate-N-alkylated cyclam-based ligand has previously demonstrated fast complexation process, high kinetic inertness and important thermodynamic and electrochemical stability with respect to natural copper. In this work we first developed a new synthetic route to obtain HTE1PA in good yields. Then, we investigated HTE1PA chelation properties towards copper-64 and assessed in vitro and in vivo stability of the resulting compound.
METHODS: Radiolabeling of HTE1PA with copper-64 was tested at different ligand concentrations in ammonium acetate medium. In vitro stability study was carried out by incubating [(64)Cu]TE1PA complex in human serum at both 37°C and 4°C; chromatographic controls were performed over 24h. Biodistribution, pharmacokinetic and hepatic metabolism of [(64)Cu]TE1PA were conducted in BALC/c mice in comparison with [(64)Cu]acetate and [(64)Cu]DOTA, used as a reference ligand.
RESULTS: The promising results obtained for natural copper complexation were confirmed. HTE1PA was quantitatively radiolabeled in 15 min at room temperature. The resulting complex showed high serum stability. [(64)Cu]TE1PA induced a significant uptake in the liver and kidneys at early biodistribution time point. Nevertheless, a high speed wash out was observed at 24h leading to significantly lower uptake into the liver compared to [(64)Cu]DOTA. The metabolism study was consistent with a high resistance to transchelation as the initial uptake into liver matches with the intact form of [(64)Cu]TE1PA.
CONCLUSION: Despite the partial elimination of HTE1PA - as copper-64 complex - through the hepatic route, its high selectivity for copper and its resistance to transchelation make it a promising ligand for antibody radiolabeling with either copper-64 or copper-67.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chelating agents; Copper radioisotopes; Cyclam; DOTA; Metabolism; Radiopharmaceuticals

Mesh:

Substances:

Year:  2013        PMID: 24440584     DOI: 10.1016/j.nucmedbio.2013.12.009

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

1.  Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation.

Authors:  Marianna Tosato; Marco Verona; Chiara Favaretto; Marco Pometti; Giordano Zanoni; Fabrizio Scopelliti; Francesco Paolo Cammarata; Luca Morselli; Zeynep Talip; Nicholas P van der Meulen; Valerio Di Marco; Mattia Asti
Journal:  Molecules       Date:  2022-06-28       Impact factor: 4.927

2.  Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

Authors:  Camille Martin; Claire Kizlik-Masson; André Pèlegrin; Hervé Watier; Marie-Claude Viaud-Massuard; Nicolas Joubert
Journal:  MAbs       Date:  2018-01-09       Impact factor: 5.857

3.  Development and Evaluation of an 18F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression.

Authors:  Diana Brickute; Marta Braga; Maciej A Kaliszczak; Chris Barnes; Doreen Lau; Laurence Carroll; Elizabeth Stevens; Sebastian Trousil; Israt S Alam; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Mol Pharm       Date:  2019-04-03       Impact factor: 4.939

4.  Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety.

Authors:  Judith Anna Delage; Silvano Gnesin; John O Prior; Jacques Barbet; Patricia Le Saëc; Séverine Marionneau-Lambot; Sébastien Gouard; Michel Chérel; Mickael Bourgeois; Niklaus Schaefer; David Viertl; Julie Katrin Fierle; Steven Mark Dunn; Alain Faivre-Chauvet
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

5.  Relevance of Palladium to Radiopharmaceutical Development Considering Enhanced Coordination Properties of TE1PA.

Authors:  Julie Pineau; Luís M P Lima; Carlos Platas-Iglesias; Jan Rijn Zeevaart; Cathryn H S Driver; Nathalie Le Bris; Raphaël Tripier
Journal:  Chemistry       Date:  2022-06-10       Impact factor: 5.020

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.